-
公开(公告)号：US20190085068A1
公开(公告)日：2019-03-21
申请号：US16111659
申请日：2018-08-24
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Barbara BRANNETTI , Emma Michelle CAMPBELL , Beate DIEFENBACH-STREIBER , Adina EBERTH , Christian Carsten Silverster KUNZ , Sylwia MARSHALL , Jean-Michel Rene RONDEAU , Jean-Marc Alfred SCHLAEPPI , Gino Anselmus VAN HEEKE
Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
公开(公告)号：US20250034240A1
公开(公告)日：2025-01-30
申请号：US18634286
申请日：2024-04-12
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Barbara BRANNETTI , Emma Michelle CAMPBELL , Beate DIEFENBACH-STREIBER , Adina EBERTH , Christian Carsten Silvester KUNZ , Sylwia MARSHALL , Jean-Michel RONDEAU , Jean-Marc Alfred SCHLAEPPI , Gino Anselmus VAN HEEKE
Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
公开(公告)号：US20170260260A1
公开(公告)日：2017-09-14
申请号：US15354978
申请日：2016-11-17
Applicant: Novartis AG
Inventor： Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
-
公开(公告)号：US20220098296A1
公开(公告)日：2022-03-31
申请号：US17386429
申请日：2021-07-27
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Barbara BRANNETTI , Emma Michelle CAMPBELL , Beate DIEFENBACH-STREIBER , Adina EBERTH , Christian Carsten Silverster KUNZ , Sylwia MARSHALL , Jean-Michel Rene RONDEAU , Jean-Marc Alfred SCHLAEPPI , Gino Anselmus VAN HEEKE
Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
-
-
Search Results
4
records
(took 0.015 seconds)
